More Concern About Transfusion Requirement When Evaluating Quality of Life in Anemic Patients

Olíva, Esther Natalie; D’Angelo, Arianna; Martino, Bruno; Nobile, Francesco; Dimitrov, Borislav D.; Perna, Annalisa; Gabrilove, Janice; Sarokhan, Brenda; Crémieux, Pierre‐Yves

doi:10.1200/jco.2002.20.14.3182

Cited by 19 publications

(14 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 Among specific modular disease-oriented questionnaires, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire -C30 (EORTC QLQ-C30) has been used worldwide to evaluate QoL in cancer patients. 14,15 Recently, a health-related quality of life questionnaire for patients with hematologic diseases (QOL-E) has been reported and validated in patients affected by myelodysplastic syndromes; [16][17][18] its role in elderly patients with AML, which is closely related to myelodysplastic syndromes, is investigated in this study.…”

Section: Introductionmentioning

confidence: 99%

Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians

Olíva¹,

Nobile²,

Alimena³

et al. 2011

Haematologica

View full text Add to dashboard Cite

patients aged more than 60 years with de novo acute myeloid leukemia were enrolled in a prospective observational study. Two different quality of life instruments were employed: the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire -C30 (EORTC QLQ-C30) and a health-related quality of life questionnaire for patients with hematologic diseases (QOL-E). ResultsForty-eight patients (42.4%) received intensive chemotherapy and 65 (57.6%) were given palliative treatments. Age greater than 70 years (P=0.007) and concomitant diseases (P=0.019) had a significant impact on treatment allocation. At diagnosis, general quality of life was affected [median QOL-E standardized score 54, interquartile range 46-70; median EORTC global score 50, interquartile range 41-66]. Most patients were given a good ECOG Performance Status (< 2), which did not correlate with the patients' perception of quality of life. At multivariate analysis, palliative approaches (P=0.016), age more than 70 years (P=0.013) and concomitant diseases (P=0.035) each had an independent negative impact on survival. In a multivariate model corrected for age, concomitant diseases and treatment option, survival was independently predicted by QOL-E functional (P=0.002) and EORTC QLQ-C30 physical function (P=0.030) scores. ConclusionsQuality of life could have an important role in elderly acute myeloid leukemia patients at diagnosis as a prognostic factor for survival and a potential factor for treatment decisions.Key words: AML, elderly, intensive chemotherapy, quality of life.Citation: Oliva EN, Nobile F, Alimena G, Ronco F, Specchia G, Impera S, Breccia M, Vincelli I, Carmosino I, Guglielmo P, Pastore D, Alati C, and

show abstract

Section: Introductionmentioning

confidence: 99%

Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians

Olíva¹,

Nobile²,

Alimena³

et al. 2011

Haematologica

View full text Add to dashboard Cite

show abstract

“…After cognitive debriefing with respondents, some items were rephrased in order to improve clarity. This did not affect the test-retest comparison [12]. The first applicable version of QOL-E® V1.0 contained 37 items in six dimensions: physical (six items), functional (four items), social (five items), sexual (three items), fatigue (eight items) and MDS-specific (11 items) [17].…”

Section: Resultsmentioning

confidence: 99%

“…Transfusion requirement maintained independent significant effects on social, MDSS, TOI, and total scores. At retest, Hb levels were not associated with QOL-E© measures, whereas the transfusion requirement was a significant independent marker of TOI and physical and MDSS well-being [12].…”

Section: Figure 1 Factor Analysis Of the 48-item Draft Qol-e© Instrumentioning

confidence: 95%

“…The lack of a reliable instrument specifically designed to elicit HRQoL information from MDS patients means that it is unclear whether HRQoL impact has been fully characterized in these patients. An initial evaluation of the HRQoL instrument, FACT-An, in MDS patients observed acceptable levels of internal consistency for the physical, functional, and fatigue components of the questionnaire, whereas the seven-item non-fatigue component of the anaemia subscale was not reliable [12]. In a systematic review evaluating the use of HRQoL instruments in MDS patients, QOL-E© was the only MDS-specific HRQoL instrument reported.…”

Section: Discussionmentioning

confidence: 99%

“…Historically, there is an absence of a validated instrument to specifically assess HRQoL in MDS patients [11]. Indeed, a review of the appropriateness of existing instruments for evaluating HRQoL in myelodysplastic syndromes found that no existing instrument fully evaluated HRQoL in this patient population [12]. The lack of a specific questionnaire for HRQoL evaluation in MDS patients prompted the development and introduction of a new specific psychometric tool, the QOL-E©, a reliable multi-dimensional self-administered questionnaire that assesses how MDS affects patients' lives.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Development and validation of QOL-E© instrument for the assessment of health-related quality of life in myelodysplastic syndromes

Olíva

Nobile

Dimitrov³

2013

Open Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review

et al. 2009

View full text Add to dashboard Cite

The main treatment for many patients with Myelodysplastic Syndromes (MDS) remains red cell transfusion to attenuate the symptoms of chronic anemia. Fatigue can reduce a patient's health related quality of life (HRQoL), but there is little understanding of the optimal use of transfusions to improve this. A systematic review was performed to identify and appraise publications reporting the use of HRQoL instruments in patients with MDS. A total of 17 separate studies were identified that used 14 HRQoL instruments, but only one MDS disease specific HRQoL instrument (QOL-E) was reported. Two well established HRQoL instruments were most often used in MDS research (variants of the Functional Assessment of Cancer Therapy (FACT) and the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (QLQ-C30)). Several common problems were identified in the published literature including a lack of power calculations to detect clinically relevant changes, small sample sizes and significant attrition rates for completion of HRQoL assessments, all of which limit the strength of any conclusions. There is no consensus on the optimal transfusion regimen to improve HRQoL in transfusion-dependent MDS. Future research into HRQoL within MDS is a pressing requirement. Studies should focus on the domains that are of most clinical importance to the patient as well as traditional quantitative changes of hemoglobin concentration. Am. J. Hematol. 84:671-677, 2009. V

show abstract

More Concern About Transfusion Requirement When Evaluating Quality of Life in Anemic Patients

Cited by 19 publications

References 2 publications

Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians

Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians

Development and validation of QOL-E© instrument for the assessment of health-related quality of life in myelodysplastic syndromes

Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review

Contact Info

Product

Resources

About